Skip to content
PepiScreen

Know your peptides before you buy.

Category: Regulatory update

Is retatrutide approved yet? Where it stands in October 2026, and what is really in the vials being sold

Retatrutide update: triple agonist targeting GLP-1, GIP and glucagon receptors

Retatrutide is not approved anywhere. Lilly files with the FDA in Q1 2027. What the trials show, when it could arrive, and what the TGA found in a vial.

PepiScreen

Know your peptides before you buy.

All rights reserved